High cytoplasmic expression of p27 Kip1 is associated with a worse cancer-specific survival in clear cell renal cell carcinoma

BJU International

Volumn 109, Issue 10, 2012, Pages 1565-1570

  Kruck, Stephan ^a   Merseburger, Axel S ^b   Hennenlotter, Joerg ^a   Scharpf, Marcus ^a   Eyrich, Christian ^a   Amend, Bastian ^a   Sievert, Karl Dietrich ^a   Stenzl, Arnulf ^a   Bedke, Jens ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

cancer specific survival; cytoplasmic localization; p27 Kip1; progression; RCC; targeted therapy

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCORING SYSTEM; TISSUE DISTRIBUTION; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOPLASM; DISEASE PROGRESSION; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GERMANY; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84860344471     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10649.x     Document Type: Article

References (32)

1. Ljungberg B, Hanbury DC, Kuczyk MA, et al,. Renal cell carcinoma guideline. Eur Urol 2007; 51: 1502-10
2. Kruck S, Merseburger AS, Gakis G, Kramer MW, Stenzl A, Kuczyk MA,. An update on the medical therapy of advanced metastatic renal cell carcinoma. Scand J Urol Nephrol 2008; 42: 501-6
3. Borriello A, Bencivenga D, Criscuolo M, et al,. Targeting p27(Kip1) protein: its relevance in the therapy of human cancer. Expert Opin Ther Targets 2011; 15: 677-93
4. Nickeleit I, Zender S, Kossatz U, Malek NP,. p27kip1: a target for tumor therapies? Cell Div 2007; 2: 1-6
5. Kawamata S, Sakaida H, Hori T, Maeda M, Uchiyama T,. The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines. Blood 1998; 91: 561-9
6. Bjorklund MA, Vaahtomeri K, Peltonen K, et al,. Non-CDK-bound p27 (p27(NCDK)) is a marker for cell stress and is regulated through the Akt/PKB and AMPK-kinase pathways. Exp Cell Res 2010; 316: 762-74
7. Graff JR, Konicek BW, McNulty AM, et al,. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000; 275: 24500-5
8. Haitel A, Wiener HG, Neudert B, Marberger M, Susani M,. Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal cell carcinoma and their prognostic significance. Urology 2001; 58: 477-81
9. Hedberg Y, Davoodi E, Ljungberg B, Roos G, Landberg G,. Cyclin E and p27 protein content in human renal cell carcinoma: clinical outcome and associations with cyclin D. Int J Cancer 2002; 102: 601-7
10. Migita T, Oda Y, Naito S, Tsuneyoshi M,. Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer 2002; 94: 973-9
11. Dahinden C, Ingold B, Wild P, et al,. Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res 2010; 16: 88-98
12. Sgambato A, Camerini A, Genovese G, et al,. Loss of nuclear p27(kip1) and alpha-dystroglycan is a frequent event and is a strong predictor of poor outcome in renal cell carcinoma. Cancer Sci 2010; 101: 2080-6
13. Hennenlotter J, Ohneseit PA, Simon P, et al,. PTEN and p27Kip1 are not downregulated in the majority of renal cell carcinomas-implications for Akt activation. Oncol Rep 2008; 19: 1141-7
14. Anastasiadis AG, Calvo-Sanchez D, Franke KH, et al,. p27KIP1-expression in human renal cell cancers: implications for clinical outcome. Anticancer Res 2003; 23: 217-21
15. Cho DC, Cohen MB, Panka DJ, et al,. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 2010; 16: 3628-38
16. Kim J, Jonasch E, Alexander A, et al,. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res 2009; 15: 81-90
17. Kudo Y, Kitajima S, Ogawa I, Kitagawa M, Miyauchi M, Takata T,. Small interfering RNA targeting of S phase kinase-interacting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation. Mol Cancer Ther 2005; 4: 471-6
18. Viglietto G, Motti ML, Bruni P, et al,. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002; 8: 1136-44
19. Liang J, Zubovitz J, Petrocelli T, et al,. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002; 8: 1153-60
20. Shin I, Yakes FM, Rojo F, et al,. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002; 8: 1145-52
21. Jiang Y, Zhao RC, Verfaillie CM,. Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity. Proc Natl Acad Sci USA 2000; 97: 10538-43
22. Baldassarre G, Belletti B, Bruni P, et al,. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J Clin Invest 1999; 104: 865-74
23. Zhou L, Huang Y, Li J, Wang Z,. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 2010; 27: 255-61
24. Pantuck AJ, Seligson DB, Klatte T, et al,. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007; 109: 2257-67
25. Hidaka T, Hama S, Shrestha P, et al,. The combination of low cytoplasmic and high nuclear expression of p27 predicts a better prognosis in high-grade astrocytoma. Anticancer Res 2009; 29: 597-603
26. Kononen J, Bubendorf L, Kallioniemi A, et al,. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-7
27. Chu S, McDonald T, Bhatia R,. Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors. Leukemia 2010; 24: 779-87
28. Jackson RJ, Adnane J, Coppola D, Cantor A, Sebti SM, Pledger WJ,. Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene 2002; 21: 8486-97
29. Tomoda K, Kubota Y, Kato J,. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 1999; 398: 160-5
30. Serres MP, Zlotek-Zlotkiewicz E, Concha C, et al,. Cytoplasmic p27 is oncogenic and cooperates with Ras both in vivo and in vitro. Oncogene 2011; 30: 2846-58
31. Katagiri Y, Hozumi Y, Kondo S,. Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo. J Dermatol Sci 2006; 42: 215-24
32. Jiang F, Caraway NP, Li R, Katz RL,. RNA silencing of S-phase kinase-interacting protein 2 inhibits proliferation and centrosome amplification in lung cancer cells. Oncogene 2005; 24: 3409-18